Difference between revisions of "Siltuximab (Sylvant)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (PeterYang moved page Siltuximab (CNTO 328) to Siltuximab (Sylvant): brand name, FDA approval)
(14 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 +
==General information==
 +
Class/mechanism: Human-mouse chimeric monoclonal antibody which binds interleukin-6 (IL-6).  Siltuximab prevents IL-6 from binding to soluble and membrane-bound IL-6 receptors.  Blocking IL-6 activity interferes with its processes such immunoglobulin secretion.  Systemic manifestations in patients with multicentric Castleman’s disease (MCD) has been associated with overproduction of IL-6.<ref name=insert>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf Siltuximab (Sylvant) package insert]</ref><ref>[[:File:Siltuximab.pdf | Siltuximab (Sylvant) package insert (locally hosted backup)]]</ref><ref>[http://www.sylvant.com/ Sylvant manufacturer's website]</ref>
 +
<br>Route: IV
 +
<br>Extravasation: no information
 +
 +
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 +
 
==Diseases for which it is used==
 
==Diseases for which it is used==
*[[Multiple myeloma]]
+
*[[Castleman disease]]
 +
 
 +
==Patient drug information==
 +
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf#page=16 Siltuximab (Sylvant) package insert PDF pages 16-17]<ref name="insert"></ref>
 +
 
 +
==History of changes in FDA indication==
 +
*2014-04-23: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm FDA approved] for the treatment of patients with [[Castleman disease | multicentric Castleman’s disease (MCD)]] who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. ''(Based on CR016705)''
 +
 
 +
==Also known as==
 +
*'''Code name:''' CNTO-328
 +
*'''Brand name:''' Sylvant
 +
 
 +
==References==
 +
<references/>
 +
 
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
 
 +
[[Category:Anti-IL-6 antibodies]]
 +
[[Category:Castleman disease medications]]
 +
 
 +
[[Category:FDA approved in 2014]]

Revision as of 12:08, 19 August 2023

General information

Class/mechanism: Human-mouse chimeric monoclonal antibody which binds interleukin-6 (IL-6). Siltuximab prevents IL-6 from binding to soluble and membrane-bound IL-6 receptors. Blocking IL-6 activity interferes with its processes such immunoglobulin secretion. Systemic manifestations in patients with multicentric Castleman’s disease (MCD) has been associated with overproduction of IL-6.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: CNTO-328
  • Brand name: Sylvant

References